Peiminine treatment reduced both MAPK and NF-κB signaling in DNCB-induced atopic dermatitis skin tissue, suggesting its effectiveness in alleviating dermatitis symptoms by inhibiting these key inflammatory pathways [30]. This evidence concerns the gene NFKB1 and dermatitis.